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Background: In Australia, economic evaluation is an important tool in 
prioritising healthcare spending. Adverse events of chemotherapy affect patients’ 
physical health and quality of life; however, they are often excluded from 
chemotherapy economic evaluations. This thesis explores the incidence, costs and 
consequences of chemotherapy adverse events and the implications for cost-
effectiveness.  
Key Objectives:  
1. Examine how adverse events are incorporated into models of chemotherapy 
cost-effectiveness. 
2. Develop Australia-based models of costs and consequences of four common 
adverse events. 
3. Estimate incidence of adverse events in clinical practice. 
4. Estimate costs of adverse events in clinical practice. 
5. Compare rates of adverse events in clinical practice with rates reported in 
clinical trials.  
Methods: There are four components to this research. The first is a systematic 
review examining how adverse events are incorporated into existing models of 
chemotherapy cost-effectiveness (Objective 1). The second is the use of decision 
analytic modelling to develop models of the costs and consequences of diarrhoea, 
nausea/vomiting, anaemia and neutropoenia. These can then become standard 
components of future models of chemotherapy cost effectiveness (Objective 2). 
The third is the use of regression to estimate the incidence and costs of adverse 
events (Objectives 3 and 4) in an administrative dataset linked to routinely 
collected data on pharmaceutical and medical service use. Finally, an analysis of a 
prospective cohort of 482 individuals undergoing chemotherapy examines the 
frequency of adverse events (Objective 3) in comparison with those reported in 
clinical trials (Objective 5).  
Results: The systematic review revealed that adverse events are not included in 
models of chemotherapy cost-effectiveness in any rigorous way. The models 
developed demonstrate that rigorous, systematic consideration of the key costs 
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and consequences of adverse events is possible, and provide a standard way to 
include adverse events in future models. Older or sicker individuals in the 
administrative dataset were more likely to experience adverse events, although 
incidence was low. Mean healthcare costs significantly increased with treatment 
for nausea, anaemia or neutropoenia but not diarrhoea. The prospective cohort 
study identified higher rates of adverse events than reported in clinical trials, with 
low-severity events particularly common. 
Conclusions: In exploring the incidence, costs and consequences of 
chemotherapy adverse events, this thesis demonstrates that it is possible to model 
the key costs and consequences of chemotherapy adverse events, and that clinical 
practice data may reduce bias in these models. This is a significant contribution to 
determining true chemotherapy costs and consequences. 
 
